Page 490 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer
P. 490

Appendix Table C4.2. Comparison between watchful waiting and radical prostatectomy (continued)
                                        Author, Year         Study name       Comparison           Outcome            Followup      Sample size      Results                          Factors included in the
                                        [Pubmed ID]          /Database                             definition/        (yr)          per group                                         model
                                                                                                   measurement
                                        Study design                                               instrument
                                        Hadley 207           SEER-            RP vs.               Death from any     Survival      RP: 11,936;      Unweighted regression            PS: age, race/ethnicity,
                                        2010                 Medicare         conservative         cause from         was           conservative     analysis:                        marital status, tumor
                                        20944078                              management           Medicare           observed      management:  HR 0.68 (0.63, 0.74); P              characteristics, previous
                                                                                                   claims.            for up to     5879             <0.001                           health problems (based
                                        Retrospective                                                                 12 years;                      PS reweighted analysis           on NCI combined
                                        cohort                                                                        mean          [calculated      using IPTW: HR 0.65 (0.62        comorbidity index and
                                                                                                                      survival      based on the     ,0.68); P <0.001                 Medicare
                                                                                                                      free of       proportion of    PS reweighted analysis           reimbursements in the
                                                                                                                      cancer-       patients         using SMRW: HR 0.68              12 months before
                                                                                                                      specific      treated with     (0.63, 0.75); P <0.001           diagnosis), year of
                                                                                                                      death =       each             IV regression using the          diagnosis. These
                                                                                                                      73.2 mo       modality, for    previous year’s local area       variables were included
                                                                                                                                    the overall      treatment pattern for            in all multivariable
                                                                                                                                    population]      conservative management          models.
                                                                                                                                                     as an instrument:
                                                                                                                                                     HR=0.92 (0.39, 2.17);            Instrumental variable:
                                                                                                                                                     P=0.78                           the lagged (previous
                                                                                                                                                                                      year’s) local area
                                                                                                                                                                                      treatment pattern for
                                                                                                                                                                                      conservative
                                                                                                                                                                                      management.
                                        Stattin 223          NPCRSFS          RP vs.               Death from any     Median        Surveillance:    HR=0.49 (0.41, 0.57)             Age at diagnosis,
                                        2010                                  surveillance         cause, data        followup      2021                                              comorbidity,
                                        20562373                                                   obtained from      8.2 yr        RP: 3399                                          socioeconomic group,
                                                                                                   the Cause of       (IQR=7.1-                                                       risk group.
                                        Retrospective                                              Death Register     9.7 yr)
                                        cohort                                                     or review of
                                                                                                   death
                                                                                                   certificates



















                                                                                                                        C-163
   485   486   487   488   489   490   491   492   493   494   495